Decisions of DNA's Annual General Meeting and the Board of Directors

Due to the purchase of DNA shares, the Annual General Meeting adjusted the Board of Directors' proposal on the distribution of profit and decided to pay a dividend of EUR 3.50 per share, totalling EUR 29,701,980. The dividend will be paid out on 27 March 2012 for shares held by external parties on 19 March 2012.

Board members and remuneration

The Annual General Meeting decided not to change the remunerations paid to the members of the Board of Directors and its Committees.

The number of Board members was set at six. Hannu Isotalo, Jarmo Leino, Jukka Ottela, Tuija Soanjärvi and Anssi Soila continue as Board members. Juha Ala-Mursula was elected as a new member. PricewaterhouseCoopers Ltd continue as the company auditor.

At the constitutive meeting of the Board of Directors held subsequent to the Annual General Meeting, Jarmo Leino was re-elected Chairman.

Amendments to the Articles of Association

The number of the members of the Board of Directors stated in the Articles of Association was changed from six (6) to eight (8) to no less than five (5) and no more than seven (7) ordinary members. In addition, the company will domicile in Helsinki. Both amendments will come into force on 1 August 2012.

Board authorisations

The Annual General Meeting authorised the Board of Directors to decide on repurchasing a maximum of 950,000 own shares using the company's unrestricted shareholders' equity. The authorisation includes a right to decide on all terms of the share repurchase and is effective until 30 June 2013. This authorisation cancels the previous authorisation.

Moreover, the Annual General Meeting authorised the Board to decide on issuing a maximum of 950,000 shares and special rights entitling to shares. The authorisation includes a right to decide on all terms related to the issuance of shares and special rights. The authorisation is effective until 30 June 2017, and cancels the previous authorisation.

The Board of Directors was also authorised to make a decision on a conveyance of a maximum of 950,000 acquired own shares. The authorisation includes a right to decide on all terms related to the conveyance. The authorisation will be effective until 30 June 2017. The authorisations to make decisions on share issues and conveyance do not cancel each other.


More information:
Ilkka Pitkänen, CFO, DNA Ltd, tel. +358 44 044 4001, ilkka.pitkanen@dna.fi
Minna Robertson, Financial Communications Manager, DNA Ltd, tel. +358 44 044 9877, minna.robertson@dna.fi

DNA Ltd is a Finnish telecommunications company providing high-quality voice, data and TV services to private customers and corporations. In 2011, DNA recorded a turnover of EUR 728 million and an operating profit of EUR 51 million. DNA has more than three million mobile and fixed-line network customers. For more information, please visit www.dna.fi .